Skip to content

Medical Devices

Fresenius Medical Device Company Intelligence Report

 

Publication Date March 2009
Publisher Espicom
Product Type Report
Pages 44
ISBN Number not applicable
Product Code ESP00774

Price

£295.00
approximately: $447 | €329

pdf

Buy Now

print £395 ($598 | €441)

Buy Now

Order above formats by FAX

Order by Fax

Summary

Medical Device Company Intelligence Reports provide a full review of the company's activities, from its origins to its latest corporate activity, including mergers and acquisitions, agreements, divestitures, major purchasing contracts and litigation. Sections are included on products, international activities and R&D, as well as a full, in-depth five year financial analysis. An introduction to each report and a full table of contents is provided for review. More than 60 Medical Device Company Intelligence Reports are currently available.

Fresenius SE is an international healthcare group providing products and services for dialysis, hospital, and outpatient medical care. In addition, Fresenius specialises in hospital operations and offers hospital engineering and services for hospitals and other healthcare facilities.

The group comprises the business segments Fresenius Medical Care (FMC), Fresenius Kabi, Fresenius Helios and Fresenius Vamed, all of which are legally-independent entities managed by the operating parent company Fresenius SE. This group structure has been in place since 1st January 2008. Prior to this date, Fresenius Helios and Fresenius Vamed formed a single business segment called Fresenius ProServe.

Fresenius Medical Care concentrates on dialysis care, and the manufacture and marketing of products for the treatment of patients with end-stage renal disease (ESRD).

Fresenius Kabi specialises in the production and sale of products for infusion therapy and clinical nutrition as well as intravenously administered generic drugs (IV drugs) and transfusion technology. Fresenius Helios operates hospitals and had a network of 57 clinics - 56 in Germany and one in Switzerland, as of 31st December 2008. Fresenius Vamed provides engineering and services for hospitals and other healthcare facilities internationally.

The segment Corporate/Other consists of the holding activities of Fresenius SE, the IT service provider Fresenius Netcare and Fresenius Biotech. Fresenius Biotech is active in research and development in the field of antibody therapies. Corporate/Other also includes the consolidation measures conducted between the business segments.

Fresenius has an international marketing and production network consisting of about 70 production sites worldwide. Key production sites are located in the US, China, Japan, Germany and Sweden.

As of 31st December 2008, Fresenius SE owned 36.27% of the ordinary voting shares of FMC and 35.80% of the total subscribed capital of FMC. Fresenius Medical Care Management, the general partner of FMC, is a wholly-owned subsidiary of Fresenius SE. Due to this structure, FMC is fully-consolidated in the consolidated financial statements of the Fresenius Group.

At the end of 2008, Fresenius SE held 100% of the management companies of the business segments Fresenius Kabi, Fresenius Helio and Fresenius Vamed.

As of 31st December 2008, the Else Kröner-Fresenius Foundation was the largest shareholder of Fresenius SE, holding approximately 58% of the voting shares.

This report mainly concentrates on the activities and performances of FMC, which claims to be the largest dialysis company in the world, and Fresenius Kabi, which holds leading positions in Europe, Asia-Pacific, Latin America and South Africa.

Contents

  • SUMMARY OPERATING RESULTS.iii
  • OVER VIEW
    • Recent Key E vents
  • FIN ANCIAL REVIEW
    • 2008 Financial Results
      • Fresenius SE - Annual Financial Results, 2004-2008
      • Fresenius - Annual Sales and EBITDA, 2004-2008
      • Fresenius Medical Care - Annual Financial Results, 2004-2008
      • Fresenius Kabi - Annual Financial Results, 2004-2008
      • Fresenius Kabi - Annual Revenues by Geographic Region
      • Fresenius Medical Care and Fresenius Kabi - Annual Net Sales, 2004-2008
      • Fresenius Helios - Annual Financial Results, 2006-2008
      • Fresenius Vamed - Annual Financial Results, 2006-2008
      • Fresenius SE - Annual Sales by Geographic Area, 2004-2008
      • Fresenius - Annual Sales by Geographic Region, 2004-2008
      • Fresenius Medical Care
      • Fresenius Medical Care - Annual Financial Results, 2004-2008
      • Fresenius Medical Care - Annual Revenues by Geographic Area, 2004-2008
    • Five-Year Financial Data
      • Fresenius - Five-Year Financial Summary, 2004-2008 (EUR million)
    • Outlook
    • Employees
    • Fresenius SE Employees, 2004-2008
    • Fresenius - Employees by Geographic Region, 2008
  • STRATEGIC FOCUS
    • Fresenius Medical Care
  • PRODUCTS
    • Fresenius Medical Care
      • FMC - Summary of Medical Device Products
    • Dialysis Products
      • HD Products
      • Dialysis Machines
      • Dialysers
      • Other HD Products
      • FMC - Annual Sales of HD Products
      • PD Products
      • CAPD Therapy
      • APD Therapy
      • FMC - Annual Sales of PD Products
      • Renal Pharmaceuticals
    • Fresenius Kabi
      • Fresenius Kabi - Medical Device Product Summary
      • Infusion Therapy
    • Clinical N utrition
    • Fresenius Kabi - 2008 Sales by Product Sector
  • RESEARCH AND DEVELOPMENT
    • Fresenius Group Annual R&D Expenses, 2004-2008
    • Fresenius Group R&D Expenditure by Business Area, 2008
    • Fresenius Medical Care
    • Fresenius
    • Online-HDF and 5008S Haemodialysis Machine
    • Home Dialysis
    • Body Composition Monitor (BCM)
    • Sorbent Systems
    • Patents and Licences
    • Fresenius Kabi
    • Fresenius Biotech
  • MANUFACTURIN AND DISTRIBUTION
    • Fresenius Kabi
    • Fresenius Medical Care
      • Fresenius Group - Principal Manufacturing and Distribution Locations, December 2008
  • AGREEMENTS
    • Agreements Summary
  • Galenica, Luitpold Pharmaceuticals and Vifor (International)
  • National Health S ervice (UK)
  • Invibio Biomaterial S olutions
  • Bioteque
  • BTG
  • Pall Corporation
  • Haemonetics
  • Terumo Cardiovascular S ystems
  • Drger Medical
  • MERGERS AND ACQUISITIONS
    • Mergers and Acquisitions Summary
    • Bidiphar I
    • APP Pharmaceuticals
    • Dabur Pharma
    • Laboratorio S anderson
    • Renal S olutions (RSI )
    • Ribbon
    • Novartis N utrition and N estl Healthcare N utrition S pain
    • Pharmatel Fresenius Kabi
    • Production Plant in Jiangsu, China
    • Kyorin Pharmaceutical's Artificial Colloid Product Business
    • Jiate E xcelsior
    • PhosLo
    • Renal Care Group
    • Renaissance Health Care and Optimal R enal Care
    • Clinico
    • Haemotec
    • Beijing Fresenius Kabi Pharmaceutical
    • Labesfal
    • Infusia
    • Isotec N utrition
    • Dicamed
    • V Krtten Medizinische E inmalgerte
    • Edwards Lifesciences' Cardiovascular R esources
    • Everest Healthcare S ervices
    • EU FETS
    • Gertezentrale fr Bluttransfusion des sterreichischen R oten Kreuzes
    • Novamdical
    • Fresenius
    • Biotecnologia Y N utricon
    • Intramed
    • Polfa Kutno's I nfusion S olution Business
    • Franconia Acquisition
    • Total R enal Care Holdings' N on-US Operations
    • Excorim's Adsorber Business
    • Pharmacia & U pjohn's Chinese N utrition Business
    • Kolon Pharmaceuticals' Dialysis Business
    • St John Dialysis N etwork
    • Pharmacia & U pjohn's N utrition Business
    • MC Medizintechnik
    • NPBI I nternational
    • US R enal Companies
    • Caremark I nternational Homecare Business
    • Spectra Laboratories
    • Neomedica's Dialysis Operations
    • Vial Medical I nfusion S ystems
    • National Medical Care
    • Laboratorios Alpha; Alpha Marketing; Alpha Medical
    • VAMED
    • Seratronics
    • Abbott Laboratories' R enal Dialysis Division
    • Knoll AG's I nfusion, Dialysis and I rrigation S olutions Business
    • Kendall Laboratories
    • MINORITY INVESTMENTS
    • E-Wha I nternational
    • Trion Pharma
  • JOINT VENTURES
    • Frebor
    • Fresenius Kawasumi
    • Renal R esearch I nstitute
    • Sino-Swed Pharmaceutical Corp Ltd
  • DIVESTITURES
    • FMCEA Perfusion Business
    • Clayton, N orth Carolina Manufacturing Facility
    • ProReha
    • Gull Laboratories
    • Diagnostics Business
    • Homecare Business
    • Ateliers Aeronautiques S aumur
  • LITIGATION
    • Baxter I nternational
    • Baxter/Deka Products
    • Gambro
    • Nabi Biopharmaceuticals
  • KEY CORPORATE EVENTS
    • Fresenius
  • Index of Tables
    • SUMMARY OPERATING RESULTS.iii
    • Fresenius SE - Annual Financial Results, 2004-2008
    • Fresenius Medical Care - Annual Financial Results, 2004-2008
    • Fresenius Kabi - Annual Financial Results, 2004-2008
    • Fresenius Kabi - Annual Revenues by Geographic Region
    • Fresenius Helios - Annual Financial Results, 2006-2008
    • Fresenius Vamed - Annual Financial Results, 2006-2008
    • Fresenius SE - Annual Sales by Geographic Area, 2004-2008
    • Fresenius Medical Care - Annual Financial Results, 2004-2008
    • Fresenius Medical Care - Annual Revenues by Geographic Area, 2004-2008
    • Fresenius - Five-Year Financial Summary, 2004-2008 (EUR million)
    • Fresenius SE Employees, 2004-2008
    • FMC - Summary of Medical Device Products
    • Fresenius Kabi - Medical Device Product Summary
    • Fresenius Group Annual R&D Expenses, 2004-2008
    • Fresenius Group - Principal Manufacturing and Distribution Locations, December 2008
    • Agreements Summary
    • Mergers and Acquisitions Summary
  • Index of Charts
    • Fresenius - Annual Sales and EBITDA, 2004-2008
    • Fresenius Medical Care and Fresenius Kabi - Annual Net Sales, 2004-2008
    • Fresenius - Annual Sales by Geographic Region, 2004-2008
    • Fresenius - Employees by Geographic Region, 2008
    • FMC - Annual Sales of HD Products
    • FMC - Annual Sales of PD Products
    • Fresenius Kabi - 2008 Sales by Product Sector
    • Fresenius Group R&D Expenditure by Business Area, 2008